Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure

Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study.

Investors Business Daily

Bankrupt DNA testing firm 23andMe to be purchased for $256m

Drugmaker Regeneron Pharmaceuticals’ capture of genetic testing firm in bankruptcy auction raises privacy concerns

The Guardian - US

Biotechnology company Regeneron buying 23andMe for $256 million

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction

Regeneron Pharmaceuticals said Monday it will acquire substantially all of DNA-testing outfit 23andMe for $256 million after coming out on top at a bankruptcy auction.

Investors Business Daily

Billions in Buybacks: 4 Stocks Rewarding Shareholders Now

These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.

MarketBeat

What to Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report

Regeneron Pharmaceuticals is slated to release its fourth-quarter results next month, and analysts forecast a single-digit dip in its bottom-line figure.

Barchart

What to Expect From Regeneron Pharmaceuticals's Q4 2024 Earnings Report

Regeneron Pharmaceuticals is slated to release its fourth-quarter results next month, and analysts forecast a single-digit dip in its bottom-line figure.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Regeneron Culls Losses After High-Dose Eylea Sales Disappoint

Regeneron stock recovered Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.

Investors Business Daily

3 S&P 500 Stocks to Buy in 2025 With Big Rebound Potential

As markets rise, a handful of resilient stocks that were bruised could rebound over 30%, powered by strong fundamentals and bullish prospects.

Barchart

3 Nasdaq-100 Stocks With 25% to 53% Upside Potential

These three Nasdaq-100 Stocks shine as prime opportunities as analysts forecast 25% to 53% upside potential.

Barchart

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Despite Regeneron Pharmaceuticals’ significant underperformance relative to Nasdaq recently, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Benzinga

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

StockNews.com

3 Biotech Stocks That Could Deliver Big Gains

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling

Tesla led the S&P 500 index on Monday, moving toward a buy point. Regeneron Pharmaceuticals tumbled on a surprise court ruling.

Barchart

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Investors Business Daily

Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.

Investors Business Daily

Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised

The Dow fell after initially rising on the PPI inflation report on the stock market today. Analysts hiked Microsoft and Nvidia price targets.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Plunge into Profits With These 3 Biotech Stocks

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

Investors Business Daily

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High

Regeneron Pharmaceuticals put up a commanding fourth-quarter beat on Friday, helped by Praluent. REGN stock is trading at an all-time high.

Top News

Eylea Sales Soar, Regeneron Breaks Records with Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 Billion!

Regeneron's Q4 sales of Eylea skyrocketed to a staggering Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 billion in the U.S., sending shockwaves through the pharmaceutical industry. Incredible suc...

Investors Business Daily

Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Regeneron Jumps On Third-Quarter Beat As High-Dose Eylea Delivers

Regeneron Pharmaceuticals topped third-quarter forecasts on Thursday, helped by a strong launch from its high dose of Eylea. REGN stock rose.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.